Larazotide
Larazotide is a synthetic 8-amino acid peptide that modulates tight-junction function in the intestinal epithelium; off-label community use centers on leaky gut and general permeability, though the entire captured record is two mixed-efficacy reports with low confidence. In the absence of a consistent community protocol, clinician sources consistently suggest 500 mcg taken orally each day, with cycle length varying by condition. The off-label evidence base is thinner than the discourse suggests: most exploratory indications, including the seven registered celiac trials, have not posted results.
Research Evidence
Evidence shape
Larazotide sits in the low-evidence tier; its strongest trials stop at Phase 2, and the only indications with more than a single trial are celiac disease and Fabry disease. Thirteen registered trials span six indications, yet four are thin or exploratory, one is animal-only, three are single-trial long tails, and two sponsors have only three linked publications across the registered trials. A 15 percent withdrawal rate and no posted data for the listed COVID-19 indication mean most of what is registered remains unpublished.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Larazotide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Frequency
- daily
- Timing
- unspecified
- Route
- oral
- Cycle
- unspecified
10 completed trials identified; trial dosing not reliably extracted from registry data.
- Frequency
- daily
- Timing
- unspecified
- Route
- oral
- Cycle
- unspecified
Clinician protocols dose 500 µg daily oral (3 sources).
No structured protocol details captured for this tier yet.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for Larazotide, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.